Onyx Pharmaceuticals (NASDAQ: ONXX) had its target price lifted by Barclays Capital from $98.00 to $123.00 in a research note released on Monday morning, Analyst Ratings Network reports. They currently have an overweight rating on the stock.
ONXX has been the subject of a number of other recent research reports. Analysts at Maxim Group downgraded shares of Onyx Pharmaceuticals from a buy rating to a hold rating in a research note to investors on Monday. Separately, analysts at Leerink Swann reiterated an outperform rating on shares of Onyx Pharmaceuticals in a research note to investors on Monday. Finally, analysts at Canaccord Genuity set a $140.00 price target on shares of Onyx Pharmaceuticals in a research note to investors on Monday. They now have a buy rating on the stock.
Four investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. Onyx Pharmaceuticals has an average rating of Buy and an average target price of $112.40.
Shares of Onyx Pharmaceuticals (NASDAQ: ONXX) opened at 135.58 on Monday. Onyx Pharmaceuticals has a one year low of $41.26 and a one year high of $101.57. The stock’s 50-day moving average is currently $89.26. The company’s market cap is $9.862 billion.
Onyx Pharmaceuticals, Inc (NASDAQ: ONXX) is a biopharmaceutical company.